[Hot topics about early clinical trials at ASCO congress 2018: News pathways, new targets, new associations].
Fiche publication
Date publication
novembre 2018
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VIGNOT Stéphane
Tous les auteurs :
Auvray M, Baylot C, Blanc-Durand F, Borcoman E, Pons-Tostivint E, Vignot S
Lien Pubmed
Résumé
Looking at the results of the early trials presented at the 2018 American Society of Clinical Oncology (ASCO) conference can help identify the molecules and strategies that will potentially enter the practices of tomorrow. It is in this spirit that this subject has justified the attention of residents in oncology and the writing of this synthesis. Molecules that can represent breakthrough innovations are presented as well as new therapeutics under development acting on targets already validated in clinical practice and early data of checkpoint inhibitors in combination with different immunomodulators, as well as new strategies for immunotherapies (vaccines and cell therapy).
Mots clés
Combinaison, Combination, Early clinical trials, Essai clinique phase précoce, First-in-class, First-in-man, Innovation, Médecine personnalisée, Personalized medicine, Phase 1
Référence
Bull Cancer. 2018 11;105(11):1084-1093